BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260414T143000
DTEND;TZID=Europe/Brussels:20260414T153000
DTSTAMP:20260624T070323
CREATED:20260309T135321Z
LAST-MODIFIED:20260309T143349Z
UID:9503-1776177000-1776180600@www.europabio.org
SUMMARY:The EU Biotech Act: Europe’s ambition for biotechnology
DESCRIPTION:Join Director General Sandra Gallina and EuropaBio to explore the EU Biotech Act proposal\, published in December 2025. \n\n\n\nThe webinar explores the Goal of the Act\, to boost innovation\, support development of biotech products and accelerate time-to-market\, making use of industrial enablers and regulatory simplification. \n\n\n\nThis webinar will introduce the drivers behind the Biotech Act proposal plus its diverse and ambitious mechanisms to boost EU biotech delivery. It will discuss how mechanisms might work and the interlink of the Act with the wider European Legislative landscape\, and its legislative pathway into action for the EU. \n\n\n\nWebinar delegates will have the opportunity to ask Director General Gallina questions during the event and EuropaBio will publish a summary for all participants. \n\n\n\nAGENDA \n\n\n\n\n\n\n\n\n14h30: Introduction – Dr Claire Skentelbery\, Director General EuropaBio \n\n\n\n\n\n\n\n\n\n14h40: The Biotech Act in focus – Director General Sandra Gallina\, DG Health and Food Safety\, European Commission: \n\n\n\n\n\nRegulatory streamlining and facilitation in health\, food and other biotech\n\n\n\nIndustrial enablers including High Impact Strategic Projects\, Boosting innovative biotech & biosimilars\, Access to Finance\, AI and Data\, Biosecurity & Defence\n\n\n\n\n15h10: Discussion and audience Q&A \n\n\n\n15h30: Close \n\n\n\nWho should attend? If you are active within biotechnology in any sector\, you should attend to understand what the Act means for you\, how you should be involved and what happens next. \n\n\n\nRegister below \n\n\n\n\nRegistration Here
URL:https://www.europabio.org/event/the-eu-biotech-act-europes-ambition-for-biotechnology/
CATEGORIES:Biomanufacturing Platform,EuropaBio,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/03/Event-Banners-Website-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260323T163000
DTEND;TZID=Europe/Brussels:20260323T180000
DTSTAMP:20260624T070323
CREATED:20260317T081056Z
LAST-MODIFIED:20260317T081058Z
UID:9523-1774283400-1774288800@www.europabio.org
SUMMARY:Special feature: Biotech Act Part I – Dr Claire Skentelbery\, Director General EuropaBio @ BIO-Europe Spring 2026
DESCRIPTION:Join our Director General Dr Claire Skentelbery at BIO-Europe Spring on the 23rd of March for an afternoon session dedicated to the EU Biotech Act Part 1. \n\n\n\nThe EU Biotech Act represents a landmark piece of legislation aimed at positioning Europe as a global leader in biotech. Structured in two parts\, the legislative program seeks to drive competitiveness across multiple sectors. Part I of the EU Biotech Act\, published in December 2025\, focuses on advancing health innovation. Key initiatives include accelerating clinical trials\, extending intellectual property protections\, launching a robust investment program\, and introducing strategic projects designed to achieve critical mass in applied innovation. Part II\, set to be unveiled in 2026\, will shift the focus toward maximising biomanufacturing across industries\, further strengthening Europe’s biotech ecosystem. \n\n\n\nThis feature session is dedicated to the Biotech Act part\, including a Keynote and Fireside Chat. \n\n\n\n16:30 Keynote presentation: Dr Claire Skentelbery\, Director General EuropaBio \n\n\n\n17:00 Fireside chat: Dr Claire Skentelbery in discussion with Dr Tilo Mandry\, Lead International Liaison Manager IGES \n\n\n\n17:15: Session: Special feature: Biotech Act Part I – What’s in it for me? Industry panel discussionPanelists:– Dr Morgane Rousselot\, Founder\, Chairwoman and CEO\, SeaBeLife Biotech– Dr Ann Belien\, Founder & CEO\, Rejuvenate Biomed (tbc)– Andreas Prenner\, Policy Officer\, European Commission– Dr Marjo Puumalainen\, International Director\, SwedenBIO– Dr Tilo Mandry\, Lead International Liaison Manager\, IGES (Moderator) \n\n\n\nThis panel continues the EU Biotech Act Special Feature: We will discuss what the Biotech Act means for biotech companies and Europe as a biotech investment location\, and how companies can best adapt to its provisions. \n\n\n\nThere are many questions about the Biotech Act:– How will industrial clinical research be accelerated and how will this affect the development of innovative therapies?– How will the Biotech Act impact the financing of innovative biotech start-ups?– Can cell and gene therapies now be developed more quickly by companies in the EU and brought to patients more easily?– What does the extension of intellectual property protection mean for biopharmaceutical companies in practice?– Is the Act sufficiently targeted at industry and where are the risk points?– And finally\, can the EU compete globally\, particularly with the US and China\, thanks to the Biotech Act?We will discuss these and many other important aspects with the panelists and the audience. \n\n\n\n18:00: Close \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/special-feature-biotech-act-part-i-dr-claire-skentelbery-director-general-europabio-bio-europe-spring-2026/
CATEGORIES:Biomanufacturing Platform,EuropaBio,External,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/02/Event-Banners-Website-38.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260323T080000
DTEND;TZID=Europe/Brussels:20260325T200000
DTSTAMP:20260624T070323
CREATED:20260219T090517Z
LAST-MODIFIED:20260219T090524Z
UID:9470-1774252800-1774468800@www.europabio.org
SUMMARY:BIO-Europe Spring 2026
DESCRIPTION:EuropaBio is joining BIO-Europe Spring 2026. \n\n\n\nBIO-Europe Spring is Europe’s largest springtime biotech partnering event\, bringing together over 3\,700 leaders and innovators in the life sciences industry. It’s designed for partnering\, business development\, and licensing opportunities in biotechnology and pharmaceuticals. \n\n\n\n \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/bio-europe-spring-2026/
CATEGORIES:Biomanufacturing Platform,External,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/02/Event-Banners-Website-38.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260310T100000
DTEND;TZID=Europe/Brussels:20260310T110000
DTSTAMP:20260624T070323
CREATED:20260209T143814Z
LAST-MODIFIED:20260209T143816Z
UID:9448-1773136800-1773140400@www.europabio.org
SUMMARY:Navigating Biotech SME Funding: What's available\, How it works\, What's next for Europe
DESCRIPTION:Europe’s biotech sector continues to face significant financing challenges\, especially during growth and scale‑up. As the EU moves forward with the landmark Biotech Act\, this webinar explores the funding tools available today\, how companies can access them\, and what changes are needed to expand investment in European biotech. \n\n\n\nThe session will provide an overview of current EU public and blended finance options across the development pipeline\, explain how the European Investment Bank evaluates and supports biotech projects\, and offer first-hand insights from a biotech founder on securing funding from idea to market. It will also examine how upcoming EU initiatives could improve access to capital and attract more private investment. \n\n\n\nSpeakers include \n\n\n\nFelicitas Riedl\, Director of Innovation and Competitiveness at the European Investment Bank \n\n\n\nRaffael Wohlgensinger\, Founder & CEO\, Formo \n\n\n\nJessica Martinsson\, our moderator and CEO of SwedenBIO\, the Swedish Biotech Association \n\n\n\n\nRegistration Here
URL:https://www.europabio.org/event/navigating-biotech-sme-funding-whats-available-how-it-works-whats-next-for-europe/
CATEGORIES:EuropaBio,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/02/Navigating-Biotech-SME-Funding-Event-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20251015T120000
DTEND;TZID=Europe/Brussels:20251015T210000
DTSTAMP:20260624T070323
CREATED:20250505T110759Z
LAST-MODIFIED:20250814T132321Z
UID:9042-1760529600-1760562000@www.europabio.org
SUMMARY:Biotech & Biomanufacturing Policy Summit
DESCRIPTION:EuropaBio is pleased to host its third Summit focused on biotechnology & biomanufacturing. \n\n\n\nBiotechnology is a critical technology for Europe.  Delivery of innovation into market drives competitiveness\, security\, supply chain resilience plus societal and environmental goals.  Europe must be ambitious and globally aware\, with a focus on securing its biotechnology capability within fast changing global geopolitics. \n\n\n\nThe current Commission has a significant opportunity to set and deliver on the ambition needed. Legislation such as the Biotech Act\, plus the frameworks that we create for sectors including health\, agri-food and manufacturing. \n\n\n\nThe half day Summit brings together EuropaBio Members and stakeholders to understand the ambition needed for legislation\, how the EU and its Member States can deliver and recognition of global positioning needed. \n\n\n\nIt is supported by biotech product displays and EU projects\, plus evening networking reception. It will be followed by a Summit Statement and public webinar hosted in November. \n\n\n\nAgenda: \n\n\n\n12:30 Registration and lunch13:15 Welcome and Keynote session Summit keynotes bring Industry\, Parliament and Commission perspectives to Europe’s ambition for biotech and biomanufacturing and the policy framework currently in action. Commissioner Olivér Várhelyi – Commissioner for Health and Animal Welfare Markus Staempfli – EuropaBio Chair\, Vice President Europe Major Markets & Canada\, CSL Behring MEP Stine Bosse – MEP and co-chair EU Alliance of Biotech and Life Sciences14:00 Panel sessions The current legislative cluster impacting biotechnology and biomanufacturing is in focus for our panel discussions. Stakeholders from across industry\, policy and member states discuss what Europe’s ambition must be and how individual and aligned legislations can deliver.Panel 1 – Enabling EU markets How policy creates markets for biotech products and enables biomanufacturing processes.Panel 2 – Enhancing access How market pathways are vital for product and process commercial viability\, determining speed and scale of access and uptake.Panel 3 – Building the EU ecosystem How knowledge\, skills\, finance and infrastructure deliver on market potential for Europe.17:50 Pre-reception remarks18:00 Reception20:30 Close\n\n\n\nThis event will be accessible by invitation only\, for more information contact us at: communications@europabio.org and c.skentelbery@europabio.org
URL:https://www.europabio.org/event/biotech-biomanufacturing-policy-summit/
CATEGORIES:Biomanufacturing Platform,EuropaBio,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2025/05/Event-Banner-Website-Biotech-Biomanufacturing-Policy-Summit.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20250129T183000
DTEND;TZID=Europe/Brussels:20250129T203000
DTSTAMP:20260624T070323
CREATED:20241217T125548Z
LAST-MODIFIED:20250128T102313Z
UID:8543-1738175400-1738182600@www.europabio.org
SUMMARY:A Driver of European Competitiveness: The Future of European Biotech
DESCRIPTION:EuropaBio\, the European association representing Bioindustries\, will host an evening reception co-hosted by MEP Stine Bosse (Vice-Chair\, SANT) and MEP Eszter Lakos (Member\, ITRE)\, to discuss the role of the European biotech sector in making the European industry more competitive. \n\n\n\nAmbassador Søren Jacobsen\, Deputy Permanent Representative of Denmark to the EU\, and Kristin Schreiber\, Director at DG GROW\, Klaus Berend\, Director SANTE will share some remarks on their approach to the biotech sector in the new mandate. \n\n\n\nThis event is only open to EuropaBio members & invited guests\, to find out more about EuropaBio membership\, contact us through our website here.
URL:https://www.europabio.org/event/a-driver-of-european-competitiveness-the-future-of-european-biotech/
CATEGORIES:Biomanufacturing Platform,EuropaBio,Healthcare Biotech,Industrial Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/12/EUROPABIO.6788f179502696.54888785.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241119T000000
DTEND;TZID=Europe/Brussels:20241119T235959
DTSTAMP:20260624T070323
CREATED:20241029T130646Z
LAST-MODIFIED:20241030T124012Z
UID:8442-1731974400-1732060799@www.europabio.org
SUMMARY:SME roundtable: Towards globally competitive European SMEs
DESCRIPTION:Europe is home to a vibrant community of Biotechnology SMEs contributing to the modernisation of the European industry. European biotechnology SMEs are the main drivers for innovation in healthcare\, food and feed\, industrial processes and manufacturing. \n\n\n\nThe Initiative on “Boosting Biotechnology and Biomanufacturing in the EU” published by the European Commission in March 2024 provides great prospects for EU SMEs. It highlights the EU ambition to deliver the benefits of biotechnology to support EU competitiveness and innovation alongside other global regions. One objective of the initiative is to identify ways to streamline EU legislation and its implementation to reduce Single Market fragmentation\, explore potential simplification of regulatory processes\, and shortening the time to market of biotechnological innovations. \n\n\n\nIn order to meet this objective\, EuropaBio\, the voice of biotechnology industries in Europe\, will be hosting this roundtable to work as partners with all relevant stakeholders to guarantee the success of this Initiative. This roundtable session aims to provide a discussion forum for SME participants active in the sector to share their main driving forces and obstacles to accessing global markets and supply chains. The session will explore the essential elements required to speed up EU market access of biotech products.  \n\n\n\nThis event will be followed by a dedicated report exploring the sessions outcomes. \n\n\n\nFor more information\, contact: communications@europabio.org
URL:https://www.europabio.org/event/sme-roundtable-towards-globally-competitive-european-smes/
CATEGORIES:EFIB,EuropaBio,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/10/External-Events-Banners-600-×-200px-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240710T080000
DTEND;TZID=Europe/Brussels:20240711T170000
DTSTAMP:20260624T070323
CREATED:20240531T135225Z
LAST-MODIFIED:20240531T135227Z
UID:7893-1720598400-1720717200@www.europabio.org
SUMMARY:CURIOUS­ FUTURE INSIGHT™ CONFERENCE
DESCRIPTION:Over the millennia science & technology have steadily advanced\, but key unsolved challenges remain\, and much more is possible. The Curious – Future Insight™ Conference brings together some of the world’s brightest scientists and most accomplished innovators to present their work and explore the future of science and technology\, solving the challenges of today and enabling the dreams of a better tomorrow. \n\n\n\nThe Curious – Future Insight™ conference featurestop speakers and Nobel laureates from all over theworld\, among them: \n\n\n\n\nEmmanuelle Charpentier\, MPI (2018)\n\n\n\nSteven Chu\, Stanford University (2024)\n\n\n\nRobert Langer\, MIT (2024)\n\n\n\nSatya Nadella\, CEO Microsoft (2018)\n\n\n\nUğur Şahin\, CEO BioNTech (2024)\n\n\n\nRandy Schekman\, Berkeley (2024)\n\n\n\nThomas C. Südhof\, Stanford University (2024\, 2022)\n\n\n\nCraig Venter\, Craig Venter Institute (2018)
URL:https://www.europabio.org/event/curious-future-insight-conference/
CATEGORIES:Biomanufacturing Platform,External,Healthcare Biotech,Industrial Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/05/Curious-Insights-Banner-600-×-200px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240124T120000
DTEND;TZID=Europe/Brussels:20240124T150000
DTSTAMP:20260624T070323
CREATED:20240109T104014Z
LAST-MODIFIED:20240116T095205Z
UID:7234-1706097600-1706108400@www.europabio.org
SUMMARY:EU pharmaceutical legislation - Europe’s biotech innovation in the balance?
DESCRIPTION:Event agenda \n\n\n\n12:00: Registration opens \n\n\n\n12:30: Panel starts \n\n\n\n13:45: Panel close and networking lunch \n\n\n\n15:00: Close \n\n\n\nConfirmed Speakers \n\n\n\nTomislav Sokol MEPMember SANT Committee\, European Parliament \n\n\n\nHilde StevensCo-director\, Institute for Interdisciplinary Innovation in Healthcare (I3H)\, ULB \n\n\n\nKristin ThompsonChief Operating Officer\, eureKARE \n\n\n\nVivian TsevelekiChief Operating Officer\, theraCell \n\n\n\nMore to be announced soon \n\n\n\nIntroduction \n\n\n\nIn April 2023\, the European Commission adopted a proposal for a new Directive and a new Regulation\, aimed at revising and replacing the existing General Pharmaceutical Legislation (GPL). The proposal focuses on modernising the pharmaceutical sector with a patient-centred approach\, while also fully supporting an innovative and competitive industry. \n\n\n\nThrough the proposal\, the EU aims to offer an attractive and innovation-friendly environment for research\, development\, and production of medicines in Europe. The EU plans to create this environment by promoting world-class innovation\, governed by stable and consistent rules that keep pace with innovation and which increase competitiveness while reducing red tape and costs. \n\n\n\nOne of the sectors impacted by the proposal is that of biotechnology\, which has been instrumental in the discovery and development of therapies\, diagnostics\, vaccines and\, most importantly\, advanced medicines. These ‘next generation medicines’ are delivered through a complex and interdependent biotechnology ecosystem\, where companies of all sizes contribute to establishing a pathway to patients. \n\n\n\nJoin this Euractiv Hybrid Conference to discuss Europe’s biotech innovation in light of the EU’s reform of the General Pharmaceutical Legislation.  \n\n\n\nQuestions to be discussed include: \n\n\n\n\nHow can Europe’s biotechnology industry maintain its competitiveness in the global medical market?\n\n\n\nHow can we establish a framework that fosters the growth of small biotech innovators?\n\n\n\nWhat are the reactions of investors to the challenges faced by small biotech companies\, and how do these reactions influence the trajectory of innovation in the biotech industry?\n\n\n\nWhat strategies can be employed to establish a successful innovation pathway for biotech companies\, while considering and aligning with the objectives of the reformed GPL?
URL:https://www.europabio.org/event/eu-pharmaceutical-legislation-europes-biotech-innovation-in-the-balance/
CATEGORIES:All,EuropaBio,External,Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/01/EuropaBio.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231011T133000
DTEND;TZID=Europe/Brussels:20231011T150000
DTSTAMP:20260624T070323
CREATED:20230920T110911Z
LAST-MODIFIED:20230920T110912Z
UID:6861-1697031000-1697036400@www.europabio.org
SUMMARY:SMEs in a Changing World: The Impact of the Revision of the Pharmaceutical Legislation on Europe’s innovative SMEs
DESCRIPTION:In April 2023\, the European Commission published new legislative proposals to revise the EU’s long-standing pharmaceutical legislation and ensure it can meet the challenges of the 21st century. The revision will redefine the regulatory framework for medicines and have a significant impact on the global innovation ecosystem. \n\n\n\nAs emerging and small companies have become innovation drivers\, responsible for over two-thirds of the R&D pipeline that will become the medicines of tomorrow\, changing the rule book that has helped build Europe’s small company ecosystem over the last 20 years is going to have consequences for start-ups\, emerging and small companies looking to first enter the market but also on mid-size companies looking for growth opportunities in Europe. \n\n\n\nThis event will be an opportunity to highlight the role of small and mid-size companies in developing medicines for patients\, assess the foreseeable impacts of the revision on those companies\, and hear directly from them what they need from the revision to continue their journey in Europe.
URL:https://www.europabio.org/event/smes-in-a-changing-world-the-impact-of-the-revision-of-the-pharmaceutical-legislation-on-europes-innovative-smes/
CATEGORIES:EuropaBio,External,Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/09/Event-Banners-Website.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230228T110000
DTEND;TZID=Europe/Brussels:20230228T121500
DTSTAMP:20260624T070323
CREATED:20230117T135652Z
LAST-MODIFIED:20230118T100150Z
UID:5661-1677582000-1677586500@www.europabio.org
SUMMARY:SME BioForum: Rare diseases
DESCRIPTION:Rare Disease Day takes place on February 28th across the globe to raise awareness among policymakers and the public about rare diseases and their impact on patient’s lives and their families. \n\n\n\nBuilding on the latest SME BioForum on Advanced Therapy Medicinal Products (ATMPs)\, EuropaBio – the European Association for Bioindustries will mark this day by hosting an online\, invite-only SME BioForum solely dedicated to rare diseases. The event will take place from 11h00 to 12h15 CET. \n\n\n\nThe meeting is entirely SME driven. SME participants will connect with their peers\, share their experiences and discuss the current regulatory and incentives framework ahead of the revision of the pharmaceutical legislation and the legislation on orphan and pediatric medicines. \n\n\n\nIf you have any queries or want further details\, please get in touch with José Peres at j.peres@europabio.org. \n\n\n\n\nSME BioForum 2022 Report: Advanced Therapy Medicinal Products
URL:https://www.europabio.org/event/sme-bioforum-rare-diseases/
CATEGORIES:Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/SME-BioForum-Rare-Diseases_Event_Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20221213T110000
DTEND;TZID=Europe/Brussels:20221213T121500
DTSTAMP:20260624T070323
CREATED:20221006T094946Z
LAST-MODIFIED:20221207T150549Z
UID:5169-1670929200-1670933700@www.europabio.org
SUMMARY:SME BioForum 2022 - the voice of SMEs for a competitive\, sustainable and healthy Europe
DESCRIPTION:EuropaBio – the European Association for Bioindustries is delighted to invite you to its first public SME BioForum event – “SME BioForum 2022 – the voice of SMEs for a competitive\, sustainable and healthy Europe.” \n\n\n\nThroughout 2022\, EuropaBio SME Platform\, representing Europe’s biotechnology SME community across healthcare and industrial biotechnology\, organised two inaugural SME BioForum sessions. The Platform gathered European SME executives to discuss the latest biotechnology commercial developments\, company challenges\, and how the European landscape impacts their ability to grow and deliver products and services to the market. \n\n\n\nIn our first session dedicated to Advanced Therapy Medicinal Products (ATMPs)\, SME executives discussed their main challenges to growth\, focusing on Europe’s Market fragmentation\, Regulatory pathways and other bottlenecks. The second SME BioForum session dedicated to Europe’s Green transition was hosted at EuropaBio’s flagship conference\, the European Forum for Industrial Biotechnology and the Bioeconomy in Vilnius\, Lithuania. In this session\, SME leaders discussed how European SMEs are driving Europe’s Green transition through Biomanufacturing\, Incentives for disruptive technologies and Data use and Digital applications. \n\n\n\nClosing this year\, EuropaBio will host this online event. Our SME participants and European policymakers will join us to present and debate the latest policy developments for ATMPs and Europe’s Green transition and share their recommendations for achieving a competitive\, sustainable\, healthy Europe. \n\n\n\nJoin us online for an engaging discussion on December 13\, 11h00 – 12h15 CET. \n\n\n\nSpeakers \n\n\n\n\nAhmed Bouzidi\, Managing Director Europe & VP International BD\, Trinomab Biotech\n\n\n\nLinda Dijkshoorn\, CEO\, EV Biotech\n\n\n\nPaschalia Koufokotsiou\, Pharmaceutical and Health Policy\, DG SANTE\, European Commission\n\n\n\nMiranda Lindsay-Fynn\, Commercial Director\, Bio-Sep\n\n\n\nAndré Meyer\, SME Envoy Network\, Outreach activities coordination\, DG GROW\, European Commission\n\n\n\nMaria Luísa Nolli\, EuropaBio SME Platform Chair\n\n\n\nClaire Skentelbery\, EuropaBio Director-General\n\n\n\nVivian Tseveleki\, COO\, Theracell\n\n\n\nTal Zeltzer\, CTO\, Phytolon\n\n\n\n\n\nRegister here
URL:https://www.europabio.org/event/sme-bioforum-2022-the-voice-of-smes-for-a-competitive-sustainable-and-healthy-europe/
CATEGORIES:SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/10/Event-Page.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220531T110000
DTEND;TZID=Europe/Brussels:20220531T123000
DTSTAMP:20260624T070323
CREATED:20220427T080004Z
LAST-MODIFIED:20220503T075144Z
UID:4371-1653994800-1654000200@www.europabio.org
SUMMARY:SME BioForum
DESCRIPTION:Advanced Therapy Medicinal Products (ATMPs) in Europe \n\n\n\n\n\nOn May 31st\, from 11h to 12h30 CET\, EuropaBio – the European Association for Bioindustries\, will host the first online round table discussion within its new SME BioForum. This online and invite-only meeting will focus on the business environment in Europe for Advanced Therapy Medicinal Products (ATMPs) in Europe. Selected SMEs are being invited by their biotechnology association which sits within EuropaBio. \n\n\n\nThe SME BioForum will bring together senior executives from Europe’s growing SMEs within ATMPs. The moderated discussion will address commercial development challenges and how the European regulatory and market access landscape influences their growth and delivery of products to patients. \n\n\n\nFrom this BioForum\, EuropaBio and its National Association Council will undertake direct advocacy on SME priorities to key stakeholders at the national and European levels to address the legislation\, regulatory\, finance and market access issues that impact SME competitiveness. \n\n\n\nBy participating in this BioForum\, SME executives have their voices heard and represented at the highest levels in Europe. \n\n\n\nParticipants should be at senior management level\, with the ability to debate their company’s challenges for sustainable growth to profit and current developments in their national biotechnology context within their field of expertise. There is no requirement for participants to be knowledgeable of or involved in policy efforts. \n\n\n\nIf you have any queries or wish for further details\, please get in touch with José Peres at j.peres@europabio.org.
URL:https://www.europabio.org/event/sme-bioforum/
CATEGORIES:SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/04/Event-Page.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210603T140000
DTEND;TZID=Europe/Brussels:20210603T150000
DTSTAMP:20260624T070323
CREATED:20210315T132511Z
LAST-MODIFIED:20210602T083815Z
UID:1616-1622728800-1622732400@www.europabio.org
SUMMARY:EU Healthcare Biotech Policy Priorities for SMEs
DESCRIPTION:Join the EuropaBio Healthcare Biotechnology Team for a dive into EU policies that impact your current operations and will shape your future strategies. With the ongoing revision of the basic pharmaceutical legislation and of regulations for medicines for rare and paediatric diseases\, SMEs should be planning how they build and grow their businesses\, whether within the EU or outside. \n\n\n\nAbout the EuropaBio SME Platform \n\n\n\nThe SME platform is a community of SMEs across all sectors in Europe\, supported through regular online meetings around EU-level topics that impact commercial biotechnology and represented to EU stakeholders. \n\n\n\n  \n\n\n\n\nREGISTER HERE\n\n\n\n\n\n\n\n\n 
URL:https://www.europabio.org/event/eu-healthcare-biotech-policy-priorities-for-smes/
CATEGORIES:EuropaBio,Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-9-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210422T140000
DTEND;TZID=Europe/Brussels:20210422T150000
DTSTAMP:20260624T070323
CREATED:20210315T132400Z
LAST-MODIFIED:20210409T131755Z
UID:1588-1619100000-1619103600@www.europabio.org
SUMMARY:EU Industrial Biotech Policy Priorities for SMEs
DESCRIPTION:Join the EuropaBio Industrial Biotechnology Team for a dive into EU policies that impact your current operations and will shape your future strategies.  With the Green Deal\, Industrial Strategy\, Circular Economy and many more\, SMEs can take advantage of changes and opportunities to plan and grow their business. \n\n\n\nAbout the EuropaBio SME Platform \n\n\n\nThe SME platform is a community of SMEs across all sectors in Europe\, supported through regular online meetings around EU-level topics that impact commercial biotechnology and represented to EU stakeholders. \n\n\n\n \n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/eu-industrial-biotech-policy-priorities-for-smes/
CATEGORIES:EuropaBio,Industrial Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/SME-April-22-Event-Banner.png
END:VEVENT
END:VCALENDAR